United States Liquid Biopsy Market (By Circulating Biomarker, Product, Application, Cancer Types, Non-Cancer Application Types, Clinical Application, End User and Sample Type), Initiatives, Company Profiles, Recent Developments and Market Dynamics – Forec

The United States liquid biopsy market was valued at US$ 1,376.6 Million in 2024, and the market is projected to reach US$ 3,264.4 Million by 2030. Liquid biopsy tests are employed across healthcare and research settings, including hospitals, physician practices, and diagnostic as well as research laboratories, to analyze the molecular characteristics of cancer. As the second leading cause of mortality in the United States, cancer presents an escalating public health challenge driven by rising incidence rates. According to projections from the National Cancer Institute, approximately 2,041,910 new cancer cases and 618,120 related deaths are expected in 2025. In response to this growing disease burden, research institutions and cancer care organizations are increasingly implementing innovative technologies and patient-centric methodologies aimed at enhancing early detection and improving therapeutic outcomes.

For decades, tissue biopsy has served as the gold standard for cancer diagnosis. However, advancements in liquid biopsy research have positioned it as a credible and effective alternative for cancer detection. The market is anticipated to witness strong growth, driven by several key factors including the advantages of liquid biopsy over traditional solid tumor biopsy, the rising global cancer burden, growing demand for minimally invasive diagnostic procedures, and increasing public and private investment in liquid biopsy research. Additionally, supportive government initiatives are further expected to accelerate market expansion over the forecast period.

Recent Developments

• In April 2025, Guardant Health, Inc. announced a strategic collaboration with Pfizer, Inc., to support the development and commercialization of Pfizer’s oncology portfolio using the Guardant Infinity smart liquid biopsy platform.
• In April 2025, LungLife AI entered into a conditional exclusive license and distribution agreement for the commercial distribution of its LungLB test in the US with Circulogene Theranostics, Inc. a US liquid biopsy diagnostics company.
• In November 2024, Foundation Medicine, Inc. announced that it has received approval from the U.S. Food and Drug Administration (FDA) for FoundationOne Liquid CDx to be used as a companion diagnostic for TEPMETKO (tepotinib) developed by EMD Serono, the healthcare business of Merck KGaA, Darmstadt, Germany in the U.S. and Canada.

Key Highlights of the Report

• On the basis of circulating biomarkers, the circulating tumor cells (CTCs) segment dominates the United States liquid biopsy market, followed by the circulating tumor DNA (ctDNA). The growth of the circulating tumor cells (CTCs) segment within the liquid biopsy market is being driven by its capability to enable early assessment of patient prognosis and to deliver critical insights that support informed clinical decision-making.
• The cfDNA is a non-invasive screening method utilized to detect graft rejection, identify genetic mutations in cancer patients, and uncover chromosomal abnormalities in fetuses, including determination of fetal gender. The discovery of cfDNA has unlocked significant opportunities across multiple medical domains, including oncology, gynecology, transplantation, and infectious disease management.
• The extracellular vesicles (EVs) is the fastest-growing segment in the circulating biomarkers market.
• Based on product type, the Kits and Consumables segment captured largest share of the liquid biopsy market, driven by the expansion of basic research and commercial applications of liquid biopsy, the rising demand for liquid biopsy tests, and the growing need for highly reliable and specific diagnostic assays.
• The instruments segment is projected to experience the highest growth within the U.S. liquid biopsy market. These instruments enable precise detection and analysis of circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) in blood samples. The increasing adoption of advanced and automated instruments by laboratories and healthcare facilities worldwide is significantly contributing to the expansion of the liquid biopsy market.
• Based on application, the oncology segment accounted for the largest share of the U.S. liquid biopsy market. Within this segment, lung and breast cancers represented the dominant areas of application. The market growth is being fuelled by the rising incidence of cancer and the increasing volume of research focused on leveraging liquid biopsy technologies for cancer detection and management.
• The non-cancer application segment is anticipated to be the fastest-growing area of the market over the forecast period. This growth is primarily driven by the expanding use of liquid biopsy in non-invasive prenatal testing (NIPT), particularly through cell-free DNA (cfDNA) assays for detecting chromosomal trisomies (such as 13, 16, and 18), determining fetal gender, and identifying other genetic abnormalities including monosomy X and microdeletions.
• In terms of clinical application, the therapy selection segment held the largest share of the liquid biopsy market. This dominance is attributed to its effectiveness in detecting advanced-stage cancers (stages III and IV) and the growing body of research focused on expanding liquid biopsy applications to support the detection of early-stage cancers as well. Continued advancements in this area are further enhancing its role in personalized treatment planning and precision oncology.
• Based on end users, reference laboratories represent the largest and fastest-growing segment of the U.S. liquid biopsy market. This growth is primarily driven by the rising volume of liquid biopsy test samples being outsourced to these laboratories, reflecting their specialized capabilities, advanced infrastructure, and efficiency in handling high-throughput diagnostic testing.
• In terms of sample type, blood is the most commonly used and is expected to maintain its position as the largest segment in the market in the coming years, given that the majority of currently available liquid biopsy tests are based on blood samples.
• The urine sample segment is projected to experience significant growth over the forecast period, driven by increasing interest in non-invasive testing methods and the development of urine-based liquid biopsy assays.

Apelo Consulting report titled “United States Liquid Biopsy Market (By Circulating Biomarker, Product, Application, Cancer Types, Non-Cancer Application Types, Clinical Application, End User and Sample Type), Initiatives, Company Profiles, Recent Developments and Market Dynamics – Forecast to 2030” provides a complete assessment of the fast–evolving, high–growth Liquid Biopsy Market landscape.

This 306 Pages report with 76 Figures and 4 Tables has been analyzed from 13 pointers:

1. United States Liquid Biopsy Market & Forecast (2021 - 2030)

2. United States Liquid Biopsy Market Share & Forecast (2021 - 2030)

3. United States Liquid Biopsy Market & Forecast - by Circulating Biomarker (2021 - 2030)

4. United States Liquid Biopsy Market & Forecast - by Product (2021 - 2030)

5. United States Liquid Biopsy Market & Forecast - by Application (2021 - 2030)

6. United States Liquid Biopsy Oncology Market & Forecast - By Cancer Types (2021 - 2030)

7. United States Liquid Biopsy Non-Cancer Application Market & Forecast - By Types (2021 – 2030)

8. United States Liquid Biopsy Oncology Market & Forecast - by Clinical Application (2021 - 2030)

9. United States Liquid Biopsy Market & Forecast - by End User (2021 - 2030)

10. United States Liquid Biopsy Market & Forecast - by Sample Type (2021 - 2030)

11. Liquid Biopsy Initiatives

12. Company Profiles – Recent Developments

13. Liquid Biopsy Market – Market Dynamics

By Circulating Biomarker - United States Liquid Biopsy Market and Forecast

1. Circulating Tumor Cells (CTCs)

2. Circulating Tumor DNA (ctDNA)

3. Cell-Free DNA (cfDNA)

4. Extracellular Vesicles (EVs)

5. Other Circulating Biomarkers

By Product - United States Liquid Biopsy Market and Forecast

1. Kits and Consumables

2. Instruments

3. Services

By Application - United States Liquid Biopsy Market and Forecast

1. Oncology Application

• Lung Cancer
• Breast Cancer
• Colorectal Cancer
• Prostate Cancer
• Gastrointestinal Cancer
• Leukaemia
• Others

2. Non-Cancer Application

• Non-Invasive Prenatal Testing (NIPT)
• Organ Transplantation
• Infectious Disease Testing

By Clinical Application - United States Liquid Biopsy Market and Forecast

1. Therapy Selection

2. Treatment Monitoring

3. Early Cancer Screening

4. Recurrence Monitoring

By End User - United States Liquid Biopsy Market and Forecast

1. Reference Laboratories

2. Hospitals and Physician Laboratories

3. Academic and Research Centers

4. Other End Users

By Sample Type - United States Liquid Biopsy Market and Forecast

1. Blood Sample

2. Urine Sample

3. Other Fluids Sample

Liquid Biopsy Market - Company Profiles

1. Personal Genome Diagnostics (Acquired by Labcorp)

2. Guardant Health, Inc.

3. Pathway Genomics (Now OME CARE)

4. RainDance Technologies (Acquired by Bio-Rad Laboratories, Inc.)

5. Cardiff Oncology (Previously Trovagene, Inc.)

6. LungLife AI (Formerly Cynvenio Biosystems, Inc.)

7. Biocept, Inc.

8. ANGLE plc

9. MDxHealth

10. Biolidics Limited (Formerly Clearbridge Biomedics Pte Ltd)

11. Exosome Diagnostics, Inc. (Acquired by Bio-Techne Corporation)

12. Foundation Medicine, Inc

13. Roche Diagnostics (A Subsidiary of F. Hoffmann-La Roche AG)

14. Genomic Health (Now Part of Exact Sciences Corp)

15. Myriad Genetics, Inc

16. Thermo Fisher Scientific, Inc

17. QIAGEN NV

18. Bio-Rad Laboratories, Inc

19. Menarini-Silicon Biosystems

20. GRAIL

Data Sources

Apelo Consulting employs comprehensive primary and secondary research techniques in developing distinctive data sets and research material for business reports. This report is built by using data and information sourced from Proprietary Information Database, Primary and Secondary Research Methodologies, and In house analysis by Apelo Consulting dedicated team of qualified professionals with deep industry experience and expertise. Show more